News in brief: Infigratinib shows promise in advanced cholangiocarcinoma; IBD patients may be higher risk for GI symptoms with COVID-19; Australia wins bronze in healthcare service rankings

Infigratinib shows promise in advanced cholangiocarcinoma Infigratinib could offer advanced cholangiocarcinoma patients another chance at treatment, a phase II study has shown. The fibroblast growth factor receptor (FGFR) inhibitor achieved a 23.1% objective response rate (95% CI: 15.6–32.2, 25 of 108 patients) at median follow-up 10.6 months, with one complete response in a patient who ...

Already a member?

Login to keep reading.

© 2021 the limbic